FBT

Alternatives Channel

Encouraging Election Year History for this Biotech ETF

By Tom LydonSeptember 11, 2020

Featured

Biotech ETFs Still Promising Despite Hydroxychloroquine Trial

By Ian YoungJune 17, 2020

Thematic Investing Channel

There’s Still Plenty of Opportunity for Biotech Post-Coronavirus

By Tom LydonJune 16, 2020

Innovative ETFs Channel

ACADIA Pharmaceuticals Help Lift Biotech ETFs

By Max ChenSeptember 9, 2019

Innovative ETFs Channel

Biotech ETFs Strengthen After Judge Blocks Trump’s Drug Pricing Rule

By Max ChenJuly 9, 2019

Featured

8 High Flying Biotech ETFs for 2019

By Ian YoungMay 28, 2019

Relative Value Channel

12 Biggest Healthcare ETFs Ready for Sector Rebound

By Tom LydonApril 24, 2019

Equity ETFs

Biotech ETFs Climb on Biogen’s Promising Clinical Trial

By Max ChenJuly 6, 2018

Equity ETFs

Alkermes FDA Refusal: Biotech ETFs Dragged Down

By Max ChenApril 2, 2018

Equity ETFs

Biotech ETFs Pop on Celgene, Juno Deal

By Max ChenJanuary 22, 2018

Equity ETFs

Biotech ETFs Rally as Pence Promises ‘Orderly Transition’ Away from Obamacare

By Max ChenJanuary 4, 2017

Equity ETFs

Rising Rates May Hurt Small-Cap Biotech ETF Valuations

By Max ChenDecember 23, 2016

Equity ETFs

Why Trump Can Boost Biotech ETFs

By Tom LydonNovember 16, 2016

Equity ETFs

Taking the Technical Temperature of Biotech ETFs

By Tom LydonOctober 21, 2016

Equity ETFs

Another Endorsement for Biotech ETFs

By Tom LydonAugust 16, 2016

Equity ETFs

Biotech ETFs: Will the Once Hot Group Rebound?

By Tom LydonJuly 13, 2016

Equity ETFs

Expect More Election Year Volatility For Biotech ETFs

By Tom LydonJune 21, 2016

Equity ETFs

A Catalyst for Biotech ETFs

By Brenton GarenJune 6, 2016